AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
All Articles
Mantle Cell Lymphoma in 2026: Auto-Transplant Fades, BTKi Combos Lead, and Brexu-cel's 5-Year Data
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant Fades, BTKi Combos Lead, and Brexu-cel's 5-Year Data
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
Mantle Cell Lymphoma in 2026: Auto-Transplant Fades, BTKi Combos Lead, and Brexu-cel's 5-Year Data
By Preetesh Jain, MD, DM, PhD
Mantle cell lymphoma is biologically diverse, clinically unpredictable, and historically difficult to treat with sustained efficacy.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line and Early Disease Is Changing Fast
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line and Early Disease Is Changing Fast
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
HER2-Positive Breast Cancer in 2026: TDXd Enters the First Line and Early Disease Is Changing Fast
By Dr. Milana Dolezal
The treatment of HER2-positive metastatic breast cancer has undergone more transformation in the past two years than in the prior decade.
Prostate Cancer in 2026: Personalizing ADT Duration, Earlier PARP Inhibitors, and a New Bispecific
By Li Zhang, MD
From ADT duration optimization to PARP inhibitors in hormone-sensitive disease and a promising T-cell engager in mCRPC, Dr. Li Zhang maps the shift toward precision in prostate cancer care in 2026.
Prostate Cancer in 2026: Personalizing ADT Duration, Earlier PARP Inhibitors, and a New Bispecific
By Li Zhang, MD
From ADT duration optimization to PARP inhibitors in hormone-sensitive disease and a promising T-cell engager in mCRPC, Dr. Li Zhang maps the shift toward precision in prostate cancer care in 2026.
Prostate Cancer in 2026: Personalizing ADT Duration, Earlier PARP Inhibitors, and a New Bispecific
By Li Zhang, MD
From ADT duration optimization to PARP inhibitors in hormone-sensitive disease and a promising T-cell engager in mCRPC, Dr. Li Zhang maps the shift toward precision in prostate cancer care in 2026.
What Does Oncology Have to Do With Advocacy, Anyway?
By Ariana Sutherland, MSc
Ask a room full of oncologists who among them is an advocate, and most hands stay down. Now ask whether they educate patients about their care, push back on insurance denials, or speak up when something is wrong.
What Does Oncology Have to Do With Advocacy, Anyway?
By Ariana Sutherland, MSc
Ask a room full of oncologists who among them is an advocate, and most hands stay down. Now ask whether they educate patients about their care, push back on insurance denials, or speak up when something is wrong.
What Does Oncology Have to Do With Advocacy, Anyway?
By Ariana Sutherland, MSc
Ask a room full of oncologists who among them is an advocate, and most hands stay down. Now ask whether they educate patients about their care, push back on insurance denials, or speak up when something is wrong.
Asking Because We Care: Why SOGI Data Is Essential to Equitable Cancer Care
By Tiffany Go, MPA, CPCHE
LGBTQ+ patients face real cancer care disparities—and without SOGI data, they remain invisible. A health equity leader at Fred Hutch makes the case for standardized, affirming data collection across cancer care settings.
Asking Because We Care: Why SOGI Data Is Essential to Equitable Cancer Care
By Tiffany Go, MPA, CPCHE
LGBTQ+ patients face real cancer care disparities—and without SOGI data, they remain invisible. A health equity leader at Fred Hutch makes the case for standardized, affirming data collection across cancer care settings.
Asking Because We Care: Why SOGI Data Is Essential to Equitable Cancer Care
By Tiffany Go, MPA, CPCHE
LGBTQ+ patients face real cancer care disparities—and without SOGI data, they remain invisible. A health equity leader at Fred Hutch makes the case for standardized, affirming data collection across cancer care settings.
Triple Negative Breast Cancer in 2026: ADCs Move Up, Immunotherapy Stays Central, Biomarkers Lag
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
Triple Negative Breast Cancer in 2026: ADCs Move Up, Immunotherapy Stays Central, Biomarkers Lag
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
Triple Negative Breast Cancer in 2026: ADCs Move Up, Immunotherapy Stays Central, Biomarkers Lag
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice
By By Bart L. Scott, MD
The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.
The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice
By By Bart L. Scott, MD
The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.
The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice
By By Bart L. Scott, MD
The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.
Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise
By Scott Tykodi, MD, PhD
Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.
Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise
By Scott Tykodi, MD, PhD
Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.
Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise
By Scott Tykodi, MD, PhD
Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.
Ten Years of CAR-T, and Ten More to Come: A Measured Look at What the Next Decade Will Bring
By Sattva S. Neelapu, MD
A CAR-T cell therapy pioneer reflects on a decade of progress and offers measured predictions for 2036—from frontline use and dual-target CARs to in vivo delivery and beyond oncology.
Ten Years of CAR-T, and Ten More to Come: A Measured Look at What the Next Decade Will Bring
By Sattva S. Neelapu, MD
A CAR-T cell therapy pioneer reflects on a decade of progress and offers measured predictions for 2036—from frontline use and dual-target CARs to in vivo delivery and beyond oncology.
Ten Years of CAR-T, and Ten More to Come: A Measured Look at What the Next Decade Will Bring
By Sattva S. Neelapu, MD
A CAR-T cell therapy pioneer reflects on a decade of progress and offers measured predictions for 2036—from frontline use and dual-target CARs to in vivo delivery and beyond oncology.